Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38)

JACC: Cardiovascular Interventions

Volumn 6, Issue 12, 2013, Pages 1275-1281

  Ojeifo, Oluseyi ^a   Wiviott, Stephen D ^b   Antman, Elliott M ^b   Murphy, Sabina A ^b   Udell, Jacob A ^c   Bates, Eric R ^d   Mega, Jessica L ^b   Sabatine, Marc S ^b   O'Donoghue, Michelle L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

clopidogrel; clopidogrel response variability; drug metabolism; drug drug interactions; prasugrel

Indexed keywords

AMLODIPINE; ATORVASTATIN; AZELNIDIPINE; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CLOPIDOGREL; DILTIAZEM; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; MEPIRODIPINE; MEVINOLIN; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PRASUGREL; PROTON PUMP INHIBITOR; SIMVASTATIN; VERAPAMIL; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RISK FACTORS; STROKE; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890792746     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.06.014     Document Type: Article

References (26)

1. W.C. Lau, L.A. Waskell, and P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction Circulation 107 2003 32 37
2. H. Neubauer, B. Gunesdogan, C. Hanefeld, M. Spiecker, and A. Mugge Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study Eur Heart J 24 2003 1744 1749
3. W.C. Lau, C.J. Neer, A.R. Tait, D.G. Carville, K.E. Guyer, and E.R. Bates Higher doses of clopidogrel overcome the atorvastatin-clopidogrel drug-drug interaction (abstr) Circulation 112 2005 II295
4. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
5. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition Heart 96 2010 186 189
6. A.M. Harmsze, K. Robijns, and J.W. van Werkum The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response Thromb Haemost 103 2010 920 925
7. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
8. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
9. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
10. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
11. M. Kazui, Y. Nishiya, and T. Ishizuka Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
12. W.C. Lau, P.A. Gurbel, and P.B. Watkins Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
13. T.A. Clarke, and L.A. Waskell The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 2003 53 59
14. J. Saw, S.R. Steinhubl, and P.B. Berger Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
15. H. Wienbergen, A.K. Gitt, and R. Schiele Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288
16. M.J. Lim, F.A. Spencer, and J.M. Gore Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry Eur Heart J 26 2005 1063 1069
17. D. Mukherjee, E. Kline-Rogers, J. Fang, K. Munir, and K.A. Eagle Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome Heart 91 2005 23 26
18. J.M. Brophy, M.N. Babapulle, V. Costa, and S. Rinfret A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention Am Heart J 152 2006 263 269
19. J. Saw, D.M. Brennan, and S.R. Steinhubl Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 2007 291 295
20. M.J. Price, K.R. Nayak, C.M. Barker, D.E. Kandzari, and P.S. Teirstein Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
21. N. Sarafoff, L. Neumann, and T. Morath Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting Am Heart J 161 2011 605 610
22. J.B. Olesen, G.H. Gislason, and M.G. Charlot Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study J Am Coll Cardiol 57 2011 409 417
23. C.W. Good, S.R. Steinhubl, D.M. Brennan, A.M. Lincoff, E.J. Topol, and P.B. Berger Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Circ Cardiovasc Interv 5 2012 77 81
24. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
25. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
26. M.L. O'Donoghue CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango? Circulation 123 2011 468 470